Key result
LMWH prescribed for recurrent pregnancy loss lacks standard evaluation in ~53% of pregnant women.
Why the study?
Despite published guidelines and evidence against their use in some indications, LMWHs are widely prescribed during pregnancy for various indications without consistent patient evaluation.
What are the indications and evaluation patterns for low molecular weight heparin use during pregnancy?
Observational (n=147)
No
What are the indications and evaluation patterns for low molecular weight heparin use during pregnancy?
LMWH is frequently prescribed during pregnancy for indications like recurrent pregnancy loss without proper standard evaluation, contrary to published guidelines.
LMWH often prescribed for recurrent pregnancy loss without standard evaluation; leaves open whether guideline adherence improves outcomes.
The aim of this study was to analyse low molecular weight heparin (LMWH) use during pregnancy in terms of patient evaluation, treatment indication and social and financial costs. This was a retrospective analysis of patients using LMWH in their pregnancies. A total of 147 women were included in the study. The most common indications were thrombophilia (55/147, 37.4%); recurrent pregnancy loss (RPL); (47/147, 32.0%) and previous single pregnancy loss (18/147, 12.2%). In the RPL group, 53.1% of patients were not evaluated with standard tests; 31.9% of women were incompletely evaluated and 15% were properly evaluated. Out of 104 women screened for thrombophilia, 32 (32/104, 30.8%) were tested during pregnancy. Despite published guidelines and increasing scientific evidence against their use in some indications, LMWHs are prescribed widely during pregnancy for a variety of indications. Public and healthcare providers' education to change this attitude should be implemented.
No takes yet. Share an insight, caveat, or question.
Kütük et al. (2014) conducted an observational in Pregnancy (n=147). Low molecular weight heparin (LMWH) was evaluated on Indications for LMWH use and evaluation adequacy. Among 147 pregnant women using LMWH, the most common indications were thrombophilia (37.4%) and recurrent pregnancy loss (32.0%), with 53.1% of the latter group not evaluated with standard tests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: